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A B S T R A C T
Alginate hydrogels are cross-linked polymers with high water content, tuneable chemical and material prop-
erties, and a range of biomedical applications including drug delivery, tissue engineering, and cell therapy.
However, their similarity to soft tissue often renders them undetectable within the body using conventional bio-
medical imaging techniques. This leaves much unknown about their behaviour in vivo, posing a challenge to
therapy development and validation.
To address this, we report a novel, fast, and simple method of incorporating the nuclear imaging radio-metal
111In into the structure of alginate hydrogels by utilising its previously-undescribed capacity as an ionic cross-
linking agent. This enabled non-invasive in vivo nuclear imaging of hydrogel delivery and retention across the
whole body, over time, and across a range of model therapies including: nasal and oral drug delivery, stem cell
transplantation, and cardiac tissue engineering. This information will facilitate the development of novel ther-
apeutic hydrogel formulations, encompassing alginate, across disease categories.
1. Introduction
Alginate hydrogels are bio-compatible cross-linked polymers with
high water content. They are tuneable in their mechanical and chemical
properties [1–3], allowing versatile fabrication across the nano to
macro scales [4] - from aerosols [5], micro-particles [6], micro-needles
[7], capsules [8], and sheets [9], to 3D-printed shapes [10]. The bio-
compatibility and structure of alginate make it an effective support
scaffold for bioelectronics [11], therapeutic cells and tissue engineering
[12], and a versatile delivery vehicle for pro-biotics [13], small mole-
cule drugs [14], genes [15], or proteins such as growth factors [16].
This flexibility has enabled alginate to become widespread in estab-
lished consumer and medical products (Table S1), with new biomedical
applications such as on-demand controllable drug release and origami-
based tissue engineering [17] still emerging and yet to reach the clinic
[8].
However, the similarity of standard Ca2+-cross-linked alginate hy-
drogels to soft tissue hinders their detection by the main medical
imaging modalities Magnetic Resonance Imaging (MRI), X-ray
Computed Tomography (CT), and ultrasound – thereby limiting un-
derstanding of the behaviour of implanted materials in animal models
of disease and in patient populations. This lack of in vivo knowledge
compromises development of new alginate-based therapies at both the
preclinical phase, and during their translation in ongoing clinical trials
(Table S2).
To address this problem, we took inspiration from the natural metal-
chelating properties of alginate and developed a versatile method of
cross-linking alginate hydrogels with radio-metal cations to enable non-
invasive in vivo imaging with SPECT. Direct cross-linking of alginate
with nuclear imaging isotopes has not been reported previously and
offers a rapid and simple method for labelling hydrogels without al-
tering their structure and properties. Using this method we show for the
first time whole-body in vivo nuclear imaging of longitudinal retention
and clearance of alginate hydrogels for oral and nasal drug delivery,
stem cell transplantation, and cardiac tissue engineering.
We hope this labelling and imaging technique will inform upon
dosing strategies, material optimisation, safety and efficacy of novel
alginate-based therapies in biologically-relevant preclinical and clinical
environments - hence accelerating their translation into well-char-
acterised and safe therapeutic products. This method uses clinically-
available materials and imaging techniques and so is readily transla-
table.
https://doi.org/10.1016/j.biomaterials.2020.119930
Received 17 October 2019; Received in revised form 26 February 2020; Accepted 28 February 2020
∗ Corresponding authors.
E-mail addresses: peter.patrick@ucl.ac.uk (P.S. Patrick), d.stuckey@ucl.ac.uk (D.J. Stuckey).
Biomaterials 243 (2020) 119930
Available online 04 March 2020
0142-9612/ © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
2. Alginate can be cross-linked by In3+ and Zr4+
Alginate is a seaweed-derived water-soluble linear co-polymer of
mannuronic and guluronic acid. It can be cross-linked into a hydrogel
using a solution of CaCl2 or BaCl2 which gelate via ionic bonding (Ca2+
or Ba2+) to negatively-charged carboxylates (COO−) across alginate
polymers [1]. We tested the ability of InCl3 and ZrCl4 to cross-link al-
ginate, as a route to imaging 111In and 89Zr with medical imaging
modalities SPECT (Single-Photon-Emission-Computed-Tomography)
and PET (Positron-Emission-Tomography) respectively. Unlike tradi-
tional metal-based radiolabelling which requires addition of an organic
chelating group [18], direct incorporation of the radio-metal into the
hydrogel structure simplifies labelling while demonstrating the hydro-
gel's structural integrity. The respective half-lives for 111In and 89Zr of
2.8 and 3.3 days permit repeat imaging over days to weeks - a time
frame suitable for many biomedical applications.
To demonstrate In3+ and Zr4+ cross-linking, a 3% w/v sodium al-
ginate solution was drop-cast into aqueous 300 mM InCl3 and ZrCl4
solutions. This produced hydrogel beads comparable in size and shape
to those cross-linked with CaCl2 and BaCl2. X-ray Photoelectron
Spectroscopy (XPS) analysis confirmed retention of the metals in the
isolated hydrogel beads in only Ca2+, Ba2+ Zr4+ and In3+ oxidation
states (Fig. S1 and Table S3). Analysis of alginate carbon binding en-
ergies using XPS confirmed In3+ and Zr4+ co-ordination with carboxyl
and hydroxyl groups on the alginate sugar subunits (Fig. S2), as occurs
with co-ordination of calcium [19]. Chelation was also confirmed by
ATR-FTIR spectroscopy, as carboxyl, hydroxyl and ether linkages
shifted considerably from the native sodium alginate (Fig. S3, Tables S4
and S5).
The ability of alginate to bind to and retain 111InCl3 and 89ZrCl4 was
then measured with dialysis against a range of solutions. Retention of
111In in alginate dialysed against saline was good above and below
physiological concentrations (0.9% w/v), with 75.8% ± 3.3 SD re-
tention in 3% w/v alginate after 1 day (Figs. S4A and B), with an mean
loss of 1.3% per day thereafter up to 8 days. Comparable retention of
111In in CaCl2 cross-linked hydrogel beads was also measured, with
~78% retained after 24 h of dialysis against physiological saline (Fig.
S4C). In contrast 111InCl3 was rapidly lost from control saline solutions
dialysed against saline, with only 14.7% ± 3.5 SD remaining after 24 h
(Fig. S4C), demonstrating the role of alginate in retaining the metal.
Retention of 111InCl3 in 3% w/v alginate solutions dialysed against
foetal bovine serum (FBS) showed a lower retention rate of
51.4% ± 1.7 SD at 24 h, with a mean loss of 3.8% per day thereafter
up to 8 days (Fig. S4D). This suggests that cross-linking is less stable in
the presence of biological molecules, but still sufficient to enable ima-
ging over biologically-relevant timeframes. For example, this compares
favourably to clinically-established 111In-oxine labelling of cells for
SPECT imaging, which can lose as much as 70% of the label within the
first 24 h [20]. To compare the strength of alginate binding to 111In
with an established trivalent metal ion chelator, 111In-alginate was
dialysed against 2.5 mM DTPA, giving retention in the dialysis mem-
brane of 10.8% ± 1.7 SD after 24 h. This shows that though alginate
chelates 111In3+, its binding is weaker than a purpose-designed che-
lator, as might be expected. Dialysis of 111In in 1% alginate against
human serum gave retention of 62.1% ± 5.9 SD after 24 h, and
40.3% ± 4.3 SD after 7 days (Fig. S4E).
In comparison to 111In retention in alginate, 89Zr retention was
highly variable and not reproducible. This suggests that though it is
able to cross-link alginate in its Zr4+ form as shown by XPS (Figs.
S1–3), cross-linking stability is less robust than that of 111In, and may
be affected by zirconium's known pH and concentration-dependent
hydrolytic conversion to zirconyl oxychloride [21], which may hinder
its use for imaging alginate with PET in biological systems.
To demonstrate labelling stability under more physiological condi-
tions, In3+ cross-linked alginate beads were implanted subcutaneously
in mice and removed for analysis 4 and 10 days later (Fig. S5). At 4 days
XPS showed the same characteristic carbon spectrum of the pre-im-
plantation In-alginate beads in the ex vivo samples, with indium only in
its In3+ state, showing maintained cross-linking. In samples excised
after 10 days, XPS showed continued retention of indium in the sample,
albeit as In2O3, with the carbon spectra suggesting calcium cross-
linking rather than indium-cross-linking. Thus at later time points
physiological calcium appears to replace indium as a cross-linker, with
indium staying in the material as an insoluble oxide.
The versatility of the radiolabelling process was then demonstrated
across a number of therapeutically-relevant formats. Alginate beads
were synthesised using a drop-casting method, microbeads using spray
fabrication, and sheets of alginate produced using a filter paper tem-
plate (Fig. 1B–D). Macroscopic beads retained 111In activity over a
week when implanted in vivo (Fig. S8).
Only sub-nanomole amounts of radio-metal ions need to be added to
alginate solutions for in vivo detection, owing to their high specific
activity (111In = 1720 MBq/nmol) and sensitivity of detection.
Therefore, bulk physical properties of the hydrogel, including micro-
structure as observed using SEM (Fig. S6) and viscosity (Fig. S7), are
not affected even when doped at an equivalent of 1 GBq/mL alginate.
Even at this high concentration, around 10-fold higher than a realistic
clinical dose, only 1 in 43194 alginate cross-linking sites would be
occupied by 111In, assuming each metal ion binds two alginate sugar
subunits.
We then demonstrated that our alginate radiolabelling method
could be used to map the hydrogel in various clinically-relevant
Fig. 1. A. Schematic of alginate hydrogel cross-linking by calcium and radionuclides 111In3+ and 89Zr4+. Radiolabelled alginate can be made into B. beads, C.
microbeads (scale bar 200 μm), and D. sheets, and imaged with SPECT-CT or PET-CT. E. Example therapy areas of hydrogel use F. 3D SPECT-CT rendering showing
detection of 111In-alginate beads in vivo.
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scenarios, including cardiac tissue engineering, stem cell delivery, and
oral and nasal drug delivery.
3. Cardiac tissue engineering and stem cell implantation
Direct cardiac alginate injections are being evaluated as a me-
chanical support for modulation of ventricular remodelling after myo-
cardial infarction in recent clinical trials [22,23]. Material implantation
into the myocardial wall can be challenging due to pulsatile motion,
therefore imaging has a clear role in informing on delivery success,
inter-patient variability in biomaterial retention, and when repeat
dosing is necessary.
Intra-myocardial injections of (2% w/v) alginate were performed in
mice under ultrasound guidance (Fig. 2G), and imaged over a week
(Fig. 2A–C). At 2 h post-injection (Fig. 2A–C) it can be seen that the
majority of injected alginate is not retained in the heart, and is cleared
from the body over the following days via the kidney and bladder,
consistent with previous pharmacokinetic data [24]. As a control
111InCl3 without alginate was also injected intra-myocardially, which
gave a wider initial distribution in the chest cavity, and much faster
clearance (Fig. S8). Two symmetrically-arranged high signal regions
were also seen above the heart at 20 h to 7 days post-injection of 111In-
alginate (Fig. 2A), suggesting clearance of the hydrogel to the med-
iastinal lymph nodes, which was not seen after injection of 111InCl3 as a
control. The proportion of the injected alginate retained in the heart
one week after injection was 2–4%, with SPECT signal coinciding with
the myocardium in CT (Fig. 2B). The low cardiac retention fraction of
implanted material is likely due to myocardial contraction and wall
thickness of mouse hearts compared to humans, meaning alginate was
rapidly expelled from the tissues. Imaging also showed inter-animal
variability between initial fraction of implanted material in the heart of
between 4 and 8% (Fig. 2C), indicating a clear role for biomaterial fate
tracking. This experiment was then repeated using alginate labelled
with the red fluorescent dye TRITC to assess 111In co-localisation with
the implanted alginate. Ex vivo autoradiography and fluorescence mi-
croscopy of sectioned tissue both showed signal in the injection tract at
4 (Figs. S9A–C) and 10 days post-injection (Fig. 2D, S9D-I), confirming
111In retention in the implanted alginate.
In addition to the use of alginate for its native regenerative prop-
erties in the heart, it has been shown to enhance retention of injected
therapeutic mesenchymal stem cells (MSCs) [25]. To assess the inter-
actions between encapsulated cells and hydrogels in vivo, 2 × 106 lu-
ciferase-expressing MSCs were suspended in 50 μL of 111In-alginate and
injected into mouse hearts as above at 3 apical sites. In cases of suc-
cessful injection SPECT-CT and bioluminescence show good spatial
correlation between 111In-alginate and live cells respectively; this is
also seen following mis-injections into the left ventricular cavity or
pericardial space, which resulted in more disperse signals (Fig. 2E and
F). At 10 days post-implantation, hearts were removed, sectioned, and
ex vivo bioluminescence and autoradiography was performed (Fig. 2I).
This showed good spatial co-localisation between in vivo SPECT-CT
(Fig. 2H), auto-radiography, and ex vivo bioluminescence (Fig. 2I).
Fig. 2. A. Maximum intensity projection SPECT image time-course showing retention of cardiac 111In alginate implantation and excretion of non-retained material
via the kidneys and bladder B. Axial SPECT-CT sections show myocardial 111In-alginate co-localisation. C. SPECT-CT ROI activity quantification shows longitudinal
kinetics of 111In-alginate cardiac retention and excretion via the kidneys in 3 separate animals following intracardiac injection at 0 h. D. Fluorescence microscopy of
20 μm sectioned heart tissue 10 days post injection showing TRITC-alginate the injection tract, with corresponding injection tract visible on the autoradiography
image of the whole section. E. SPECT-CT of 111In-alginate + MSCs at 24 h following successful and unsuccessful injection, together with corresponding F.
Bioluminescence images from the same mice confirming the location of live cells. G. Ultrasound-guided myocardial injection of 111In-labelled alginate. H. Axial
SPECT-CT section showing co-localisation of 111In-alginate-MSCs SPECT signal with CT heart I. Ex vivo bioluminescence showing live MSCs co-localises with 111In
alginate at sites of implantation in corresponding ex vivo autoradiography of apical, mid and basal heart tissue sections from the successfully injected mouse shown in
A-D at 10 days post-injection.
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Results suggest that live donor cells remained within the 111In-alginate
at all 3 injection sites for at least ten days after injection. This approach
can be used to provide valuable in vivo information on delivery and
retention of alginate-encapsulated cells. Previous reports claim less
than 0.1% of injected stem cells typically form stable grafts in the heart
[26]. However, the use of alginate can enhance donor cell retention,
attachment, and growth conditions, providing a rationale for both
cellular and acellular use in cardiac repair [27].
4. Muscle implantation
The ability to follow alginate in muscle is important for many
emerging clinical therapies including bladder wall muscle chondrocyte
implantation for vesicoureteral reflux treatment (Table S2), and re-
generation of skeletal muscle diseases including muscular dystrophy
[28]. As a model for muscle implantation 2% (w/v) 111In-alginate so-
lution was injected into the thigh muscle of mice, and retention was
followed over a week using SPECT-CT (Fig. 3A–C, S10A,B). The pro-
portion of material successfully implanted and retained was much
higher than the cardiac model, with over 20% retained a week post-
injection (Fig. 3C). Clearance of free 111InCl3 injected in the same way
as a control was faster than 111In-alginate (Fig. S11). Using fluores-
cently-labelled TRITC-alginate, we confirmed the co-localisation of
111In signal and alginate ex vivo on cryosections from tissue removed 5
days post-implantation. Autoradiography and fluorescence imaging
showed overlapping areas of signal (Fig. 3 and S12) which could be
clearly identified as the injection tract with fluorescence microscopy
(Fig. 3E–F).
We then investigated 111In-alginate use as a support matrix for the
differentiation of mesenchymal stem cells into chondrocytes in vivo
(Fig. 3G,H, S10C,D, and Fig. S13). MSCs were suspended in 111In-al-
ginate (2% w/v) cross-linked to form solid spheres in a bath of 100 mM
CaCl2, before subcutaneous implantation. Alginate placement and de-
gradation was then monitored up to 2 weeks using SPECT-CT, showing
comparable retention of material to the flank-injected alginate. After 3
weeks the transplanted cell mass was removed and analysed histolo-
gically for the differentiation of stem cells into chondrocytes (Fig. S13).
Cells in 111In-alginate retained their ability to differentiate into
Fig. 3. SPECT-CT imaging and quantification of 111In-alginate signal in models of muscle tissue engineering, stem cell grafting, and oral drug delivery.
(A,B) SPECT-CT 3D rendering showing 111In-alginate location (2 day post injection) in the flank muscle, and (C) signal quantification following injection into the
flank muscle (n = 3, error bars show SD). The 0 day time point is 90 min post implantation (D) Autoradiography and matched fluorescence image of flank muscle 5
days post implantation showing co-localisation of TRITC-alginate and 111In signal. (E) Fluorescence and (F) brightfield microscopy images showing TRITC-alginate in
the injection tract area of the thigh muscle highlighted in the box in part D. (G) SPECT-CT 3D rendering of 111In-alginate hydrogel spheres at 24-h post implantation
and (H) quantification of signal up to two weeks after subcutaneous implantation. Points represent means (n = 3), error bars show SD. The 0 day time point is 90 min
post implantation (I)Maximum intensity projection SPECT-CT and sagittal section showing 111In-Gaviscon (10% w/v alginate) in the oesophagus and stomach at 1 h
post oral dosing. (J) Retention of 111In in Gaviscon and control saline solutions dialysed against simulated stomach acid (pH2). (K) Autoradiography and (L)
fluorescence image of small intestine (20 μm section) 75 min post-dosing, showing co-localisation of alginate and 111In signal.
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cartilage-like tissue, consistent with previous reports using non-labelled
alginate [4]. MSCs grown in 111In-Alginate spheres also showed no
change in cell growth compared to those grown in non-radiolabelled
alginate (Fig. S14). This is consistent with the literature which shows
that alginate is not taken up by cells unless their membranes are de-
liberately permeabilised [29], and the effective dose received by cells
from 111In is several orders of magnitude lower when the isotope is
outside the cell than within it [30].
As various alginate-encapsulated cell types are being investigated
for therapies, including Islets of Langerhans for diabetes [31], and he-
patocytes for acute liver failure [32], the ability to image transplanted
alginate beads as presented here could be of wide utility in under-
standing their behaviour in vivo and potential routes for optimising
transplantation strategies.
5. Oral drug delivery
Alginate is also widely used to treat gastro-oesophageal reflux dis-
ease (GORD, also GERD, or acid reflux), which affects 40% of the
Western population [33]. In addition to heartburn, GORD increases risk
of oesophageal adenocarcinoma by 8-fold [34]. Orally-dosed alginate
solutions are the best-established treatment for GORD, acting as a
mechanical floating barrier to reflux [33]. The large market size for
GORD treatments creates substantial pharmaceutical research interest
in optimising alginate-based formulations for retention in the stomach
[33,35] which is necessary for efficacy but difficult to monitor non-
invasively. We labelled an over-the-counter alginate-based anti-acid
formulation Gaviscon™ (containing 10% w/v alginate) with 111In, and
measured 111In retention following dialysis against simulated stomach
acid (pH 2 Krebs-Henseleit buffer + 1 mM deoxytaurocholate), which
showed good retention up to 4 days (Fig. 3J). We then dosed this to
mice and imaged them up to 4.5 h post-dosing with SPECT-CT. Re-
tention in the stomach was quantified, giving: 44.8% retention at
20 min post dosing, 43.9% at 1.5 h, and 37.5% at 4.5 h (Fig. 3 and S15).
For ex vivo validation 111In Gaviscon was mixed with TRITC-alginate
and dosed as above. Autoradiography and fluorescence imaging of
tissue sections showed retention of 111In-alginate in the small intestine,
confirming persistent binding (Fig. 3K,L, and S16). This shows that non-
invasive in vivo imaging was suitable for assessing delivery kinetics of
this commercial formulation. This ability to image orally-delivered al-
ginate will also be useful for the development of for other emerging oral
uses including drug delivery for diabetes mellitus [36] and (re)popu-
lation of beneficial microbiota in the gut [37].
6. Nasal drug delivery to brain
Finally, we showed that alginate could be tracked in mice after nasal
dosing, where alginate's mucoadhesive properties and viscosity suit its
use as a vehicle. This is a promising route for delivering small or macro-
molecules to the brain as it bypasses the blood brain barrier [38]. Past
studies have shown greater retention of viscous compared to non-vis-
cous fluids in the nose, however multiple interacting parameters such as
spray device and droplet size make delivery unpredictable, providing a
valuable role for imaging in quantifying delivery and retention [39,40].
We compared nasal retention of a low-viscosity control aqueous
solution containing a soluble indium chelate (111In-EDTA) to an 111In-
cross-linked 0.6% (w/v) alginate solution. Mice were dosed with 20 μL
of solution into each nostril via pipette. SPECT-CT imaging showed
significantly higher retention of 111In-alginate vs 111In-EDTA, with a
5.8-fold higher activity retention at 1 h, 35-fold at 24 h and 26-fold at
day 4.111In-alginate was still detectable at days 8 and 14 post-dosing,
whereas no signal remained in the animals receiving 111In-EDTA
(Fig. 4A–C). Gut signal was consistent with these results, showing sig-
nificantly more clearance via this route in the mice receiving the 111In-
EDTA compared to 111In-alginate (Fig. 4D).
To confirm that nasally-dosed alginate can transfer its cargo to the
brain, hydrogels were loaded with the MRI contrast Mn2+ (0.6% w/v
alginate, 10 mM MnCl2) and dosed before imaging 30 min later using
MRI (Fig. 4 e). Mn2+ in contrast to Ca2+, In3+ and Zr4+, binds poorly
to alginate and is quickly released [41]. Signal hyper-intensity of the
olfactory bulb was seen following Mn-alginate dosing but not in the
control condition (lacking Mn2+), confirming nose-to-brain delivery.
To demonstrate delivery of a more typically drug-sized small molecule
to the brain, 123I-Datscan (MW = 427.285 g/mol) was dosed as above
in 0.6% w/v alginate and detected using SPECT. Uptake of 123I-DatScan
in the basal ganglia (Fig. 4F) where it binds to presynaptic dopamine
transporters, confirms its ability to reach distant brain target regions
following nasal dosing.
Other clinical applications of nasal alginate delivery include post-
surgical application to prevent bleeding [42], with dust mite extracts
for hypo-sensitisation in rhinitis patients [43], and for controlled drug
release in the nose [44].
7. Discussion
This report extends the recent progress on chelate-free radio-label-
ling beyond its current domain of nano-materials (including: iron oxide
nanoparticles [45–47], nanophosphors [48], gold nanoparticles [49],
liposomes [50], silicon nanoparticles [51], and nanographene [52])
into the field of polymers and hydrogels. The simple and novel radio-
metal cross-linking technique we describe here uses the natural ability
of alginate to co-ordinate multivalent cations in place of the more
traditional chelate-based radiolabelling approaches which require ad-
ditional chemical modification. We have shown that alginate sugar
subunits bind In3+ ions in a similar way to the cross-linker Ca2+ which
is routinely used in biomedical applications. This allows the location of
alginate hydrogels or solutions to be measured across the anatomy in
three dimensions using non-invasive SPECT imaging. We have shown
that radio-metal incorporation does not alter mechanical hydrogel
properties and remains bound within the biomaterial to enable in vivo
imaging over biologically-relevant timescales. Though 89Zr did not turn
out to be well-suited to this labelling technique, its potential compat-
ibility with other radio-metal cations such as 64Cu2+, 68Ga3+, and
177Lu3+ for PET and SPECT imaging, as well as radiotherapy, is the
source of ongoing investigation.
We have demonstrated the versatility of this technique in a number
of mouse models of pre-clinical alginate-based interventions, showing
the in vivo biodistribution of alginate used for acellular and cellular
tissue engineering in the heart and muscle, stem cell grafting, and oral
and nasal drug delivery. The information thus acquired informs on the
success of delivery or transplantation in the target tissue, its retention
over time, clearance, off-target accumulation, and inter-patient/inter-
animal and inter-dose variability. This will be invaluable data during
the evaluation of novel alginate-based therapies in preclinical devel-
opment and clinical trials (Table S2). It will provide better under-
standing of the safety of novel treatments, their mechanisms of action,
and feedback for optimisation of formulations and dosing strategies.
This technique uses materials (alginate, 111In) and quantitative imaging
(SPECT) already available in the clinic, lowering the barrier to im-
plementation.
Though previous methods have been described to image alginate
hydrogels with fluorescence, MRI, CT, and ultrasound [53–55], these
imaging modalities variously suffer from ambiguities of detection
which are not encountered with the nuclear imaging systems that we
describe here. Fluorescence imaging is comparatively cheap and
widely-available, but suffers from poor depth penetration and quanti-
fication, unlike nuclear imaging. MRI has the advantage of better tissue
depth penetration than fluorescence, suiting it better for clinical ap-
plication and whole body imaging, while also allowing higher resolu-
tion detection of labelled material than nuclear imaging. But it is not
always possible to unambiguously detect contrast agents such as iron
oxides with MRI in certain areas of the body in which there is
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endogenous heterogeneity in signal or hypo-intense signal voids. For
example any gas filled cavity such as the nasal cavity, oesophagus,
lungs, or bowels, has its own susceptibility artefacts which prevent
quantification. With CT, endogenous contrast is provided by the bones
and soft tissue, and the mass of contrast agent needed to be in-
corporated into the hydrogel to provide signal is up to seven orders of
magnitude greater than it is for nuclear imaging [56]. This may be a
problem because introducing much larger amounts of contrast agent is
likely to alter the material properties of the hydrogel, and influence the
behaviour of encapsulated drugs or cells, unlike the (sub)nanomolar
amounts of radio-metal required for SPECT or PET. Though ultrasound
imaging is convenient and cost effective for certain applications, the
areas of the body that can be imaged are again limited, and signal
impeded by bone or pockets of gas - preventing quantification of ma-
terial distribution across the whole body. On the other hand, long-
itudinal SPECT-CT allows signal quantification across the entire
anatomy, with its use mainly restricted by the chosen isotopes’ half-life,
which limits practical detection to the order of one or two weeks in the
case of 111In. In terms of safety, 111In is typically used for diagnostic
purposes in the clinic at doses between 12 and 220 MBq per patient
[57,58]. Thus it would be realistic to assume that doses several-fold
higher than those used in this study (5–6 MBq) could be justified to
reduce imaging time or extend the time-course of material tracking
beyond the week to a fortnight demonstrated here.
In summary, we have demonstrated for the first time that alginate
can be cross-linked with a radio-metal (111In), and that this enables
imaging of its in vivo biodistribution with SPECT-CT. Nuclear imaging
allows three-dimensional non-invasive in vivo imaging with good re-
solution across the anatomy, and is available for both pre-clinical and
clinical use. Due to the versatility of alginate as a biomaterial and the
prevalence of novel emerging uses in drug delivery and regenerative
medicine, we anticipate that this labelling method will be of value to
the biomaterial community in the development, optimisation, and va-
lidation of novel alginate-based therapies.
8. Experimental section
Experimental details are provided in greater detail the supporting
information.
Fig. 4. 111In-Alginate shows enhanced retention in the nose compared to a control solution of 111In-EDTA. Maximum intensity projection SPECT-CT image time-
course showing retention of a. 111In-Alginate and b. 111In-EDTA after nasal administration. c. A significantly higher % ID is retained in the nose in the alginate group
compared to control up to 4 days (n = 3; 2-tailed T-test; *p < 0.01, **p < 0.001). d. A higher % of the injected dose is present in the abdomen in the control group,
showing gut clearance, at 90 min after dosing (0 days), vs the alginate group (n = 3; 2-tailed T-test; *p < 0.05). Error bars show SEM. e. Axial T1-weighted magnetic
resonance image showing signal hyper-intensity in the olfactory bulb after nose-to-brain delivery of Mn2+ from alginate, but not in the control condition before
dosing. f. Coronal section and dorsal maximum intensity projection SPECT-CT images showing signal in the basal ganglia following nasal delivery of 123I-DatScan in
0.6% alginate, confirming nose-to-brain delivery to pre-synaptic dopamine transporters within 2 h of dosing.
P.S. Patrick, et al. Biomaterials 243 (2020) 119930
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9. Material characterisation
XPS and ATR-FTIR were performed on hydrogel beads made using
3% w/v sodium alginate solution drop-cast into aqueous 300 mM InCl3
and ZrCl4 solutions and left to cross-link for 10 min. These were then
incubating for 30 min in distilled water three times to wash off unbound
metal salts, before freeze-drying overnight.
X-ray Photoelectron Spectroscopy (XPS) was performed using a
Thermo Scientific K-alpha spectrometer with monochromated Al Kα
radiation, a dual beam charge compensation system and constant pass
energy of 50 eV (spot size 400 μm). High-resolution peaks were used for
the principal peaks of C (1s), Na (1s), Ba (3d), Ca (2p), In (3d) and Zr
(3d). Peaks were modelled with CASA XPS software.
Attenuated Transmission Reflectance Fourier-Transform Infrared
(ATR-FTIR) spectra were recorded on a Bruker ALPHA Platinum ATR
single reflection diamond ATR between 400 cm−1 and 4000 cm−1.
10. SEM
Alginate beads were prepared for SEM using a drop casting method
with a 3% sodium alginate solution (w/v) and 300 mM CaCl2 solution
as cross-linker. Relevant molar equivalents of ZrCl4 or InCl3 were added
to the alginate solution prior to cross-linking with calcium, assuming
specific activities of 0.15 GBq/nmol and 1.85 GBq/nmol respectively.
Samples were changed through an ethanol series then stored in a fresh
solution of 100% ethanol before drying in a Quorum K850 critical point
dryer. Samples were then fractured under liquid nitrogen, and given a
5 nm gold coating in a Quorum Q150T Sputter coater. Images were
obtained at 50 000× and 70 000× magnification using a FEI Quanta
200 FEG ESEM (ThermoFisher Scientific).
11. Viscosity measurements
Viscosity measurements were made on 1 mL samples over a shear
rate range of 90–1000 s−1 using a Bohlin CVO rheometer (Malvern
Instruments). This was set up in the cone and plate geometry (60 mm,
0.995°), and the temperature maintained at 20 ± 0.05°. A gap of
25 μm was used for all experiments.
12. Radioactivity measurements
All radioactivity measurements were made using either a dose ca-
librator (Capintec Curimentor), or where appropriate an automated
high-sensitivity gamma counter (Perkin Elmer Wizard2). For in vivo
analysis of activity, regions of interest were drawn manually around
sites of injection using the CT data for anatomical reference, using
VivoQuant software (Invicro).
13. Cell culture
Luciferase-expressing D1 ORL UVA (ATCC® CRL-12424™) mouse
mesenchymal stem cells (a kind gift from Dr Arthur Taylor, University
of Liverpool) were grown in DMEM (Invitrogen, UK) including 10%
fetal bovine serum (FBS), 2 mM L-glutamine and 0.1 mM MEM non-
essential amino acids at 37 °C with 5% CO2 and 95% humidity.
Cell viability was measured as photon output 6 min after the ad-
dition of luciferin to the growth media (final concentration of 50 μg/
mL), using an optical plate-reader (Varioskan Lux, Thermo-Fisher).
Growth media was changed following each assay reading. A total of 11
alginate beads were synthesised for each condition by suspending MSCs
at a concentration of 20 million per mL in a 1.5% (w/v) alginate so-
lution. Cross-linking was done for 10 min using a 100 mM CaCl2 so-
lution, with a bead volume of 100 μL. Beads were cultured in individual
wells of an opaque cell culture dish. For the Indium condition, 111InCl3
was added to the alginate solution at 30 MBq per mL final concentra-
tion.
14. Autoradiography
For co-registration with fluorescence images, excised hearts, mus-
cles, and intestines were frozen in Optimal Cutting Temperature solu-
tion (OCT; Cellpath), and sectioned at 20 μm using a cryotome (Leica
CM3050S) onto slides (SuperFrost; ThermoScientific). Fluorescence
microscopy was done using an EVOS XL (Thermofisher) equipped with
RFP filters (Ex. 531 nm, Em. 593 nm), and whole slide fluorescence
images were obtained at 50 μm resolution (Ex. 532 nm, Em. 580) using
a Typhoon 9410 Imager (GE Healthcare). The same slides were then
exposed to a storage phosphor screen (GE Healthcare) for between
10 min and 3 days to obtain sufficient signal, which was scanned at
50 μm resolution (Typhoon 9410 Imager), and the resulting images
were processed by ImageJ (NIH, USA).
For co-registration with ex vivo bioluminescence, hearts were ex-
cised, flash frozen, and cut into 1 mm thin sections along the short axis,
before incubation with 1% TTC for 30 min. Sections were mounted on,
photographed and exposed to GP 20 × 25 cm2 phosphor screens (VWR
international LTD, U.K.) for 2 h. After this time, the screens were
scanned by a Typhoon 9410 Trio + Phosphorimager (GE Healthcare,
U.K.), (25 μm resolution, acquisition time = 2 h 30 min) and the re-
sulting images were processed by ImageJ (NIH, USA).
15. Alginate fluorescent labelling
Alginate was labelled with tetramethylrhodamine (TRITC;
Excitation maximum = 543 nm; Emission maximum = 569 nm) using
an EDC/NHSS conjugation protocol adapted from Zhu et al. [59]. To
confirm labelling, the fluorescence spectrum of the labelled alginate
was then measured using a microplate reader (VarioSkan Lux; Ther-
moFisher) with comparison to a TRITC dye solution and unlabelled
alginate (Fig. S17).
16. Histology
Alginate spheres were excised at 20 days post implantations, at
which point teratoma formation had occurred. Tissues were fixed
overnight in 4% paraformaldehyde then changed into 70% ethanol.
Samples were dehydrated and paraffin embedded before sectioning at
20 μm thickness onto glass slides and stained with Alican blue, and
counterstained with nuclear fast red solution (Sigma Aldrich product:
N3020-100 ML).
17. In vivo animal work
All animal studies were approved by the University College London
Biological Services Ethical Review Committee and licensed under the
UK Home Office regulations and the Guidance for the Operation of
Animals (Scientific Procedures) Act 1986 (Home Office, London, United
Kingdom). All animal methods were performed in accordance to in-
stitutional ethical guidelines and regulations. C57BL/6 animals were all
acquired from Charles River.
For intramyocardial delivery, 10 week old, male C57BL/6 mice
(n = 3) were anaesthetised with 2% isoflurane in 100% O2. Hearts
were visualised using ultrasound (Visualsonics Vevo 2100) and 50 μL of
2% 111In alginate with or without MSCs (4 × 107 cells/mL alginate)
was injected into the anterolateral wall of the myocardium using ul-
trasound guidance of a 30 gauge needle. Ten days later, hearts were
flushed with saline, excised and sliced for autoradiography and ex vivo
BLI.
For muscle delivery, 10 week old, male C57BL/6 mice (n = 3) were
anaesthetised with 2% isoflurane in 100% O2, and 50 μL of 2% 111In-
alginate was injected into the left thigh muscle using a 30 gauge needle.
For subcutaneous bead implantation, 2 mm diameter, 111In alginate
beads were fabricated by dropcasting of 2% (w/v) alginate pre-mixed to
a final concentration of 2 × 107mouse mesenchymal stem cells/mL into
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a bath of 100 mM CaCl2 and left to cross link for 4 min 10 week old,
male C57BL/6 mice (n = 3) were anaesthetised with 2% isoflurane in
100% O2, Fur was removed from the dorsal region, the skin was ster-
ilised and a small incision was made between the shoulder blades.
Beads (6–7 beads per animal) were implanted into the subcutaneous
space and the incision was closed with a suture.
For oral administration of 111In-labelled anti-acid treatment,
Gaviscon™ Advance Original Aniseed (Boots Plc, Tottenham Court
Road, England) was mixed with 111InCl3 at a ratio of 5 MBq per 100 μL
of Gaviscon. 10 week old, male C57BL/6 mice (n = 2) were scruffed
and voluntarily consumed the 111In-Gaviscon (100 μL) which was dis-
pensed from a pipette tip positioned next to the mouth. Mice were then
imaged with SPECT-CT at 20 min, 90 min, and 4.5 h (270 min) after
administration.
For nasal dosing of 111In-alginate, a solution was prepared to a final
concentration of 0.6% w/v alginate containing 150 MBq/mL 111InCl3.
Of this, 20 μL was administered to each of the left and right nasal
passages using a micropipette (Gilson) while the animal was scruffed,
resulting in doses of ~6 MBq 111In per animal. 10 week old, male
C57BL/6 mice (n = 3) were used per condition. As a control, mice were
administed an equal volume of 111In-EDTA (Ethylenediaminetetraacetic
acid; Sigma Aldrich) which was made prepared by mixing a 1 mM
EDTA solution (pH 7.4) with 111InCl3 to a final activity of 150 MBq/mL.
Thin layer chromatography using a 0.9% saline mobile phase was used
to confirm binding of 111In to EDTA before administration; unbound
111In will remain at the origin while 111In-EDTA will migrate with the
solvent front. For nasal dosing of 0.6% alginate containing 123I-DatScan
(20 MBq/100 μL), 20 μL was dosed per nostril using a micropipette and
SPECT-CT imaging was performed at 2 h post-dosing.
For MRI nasal dosing of Mn-alginate was done using a micropipette
to administer 20 μL of a 0.6% solution of alginate (w/v) containing
10 mM MnCl2. Imaging was performed at 30 min post dosing.
18. In vivo imaging
During all in vivo imaging, mice were maintained at 37 °C under
isofluorane breathable anaesthesia (1–2%) in oxygen. A small animal
physiological monitoring system (SA Instruments, Stony Brook, NY)
was used to monitor core body temperature and respiration rate.
SPECT data was acquired using a NanoScan SPECT-CT (Mediso)
with 1.4 mm pinholes, interfaced to a computer running Interview
Fusion software (Bartec). Images were reconstructed using HiSPECT
software, and analysed using VivoQuant software (Invicro). CT images
were acquired using a 55 kVP X-ray source, 500 ms exposure time, 180
projections, a pitch of 1.5. CT images were reconstructed in voxel size
124 × 124 × 124 μm, whereas SPECT images were reconstructed in a
256 × 256 matrix prior to being overlayed. 3D ROIs were manually
drawn and used to calculate the percentage of injected dose/organ (%
ID/organ).
PET data was acquired using a NanoScan PET-CT (Mediso) inter-
faced to a computer running Interview Fusion software (Bartec), which
was also used to reconstruct images. Data was analysed using
VivoQuant software (Invicro).
MRI data was acquired using a 9.4T horizontal bore scanner
(Varian) interfaced to a VNMRJ 3.1 (Varian) imaging console, using an
Agilent 205/120HD gradient set, 72 mm inner diameter volume coil for
RF transmission (Rapid Biomedical), and a 2 channel array surface coil
(Rapid Biomedical) for signal reception. T1-weighted images were ac-
quired using a multi slice gradient echo (TE 2.5 ms/TR 75 ms; 75° flip
angle), with a 100 × 100 × 250 μm voxel size.
In vivo Bioluminescence imaging was performed using an IVIS 200
(PerkinElmer) imaging device at 10 min post intraperitoneal injection
of D-luciferin (Promega) solution at 150 mg/kg per mouse. Ex vivo
imaging was performed immediately after cervical dislocation and
dissection of the animal.
Data availibility
Data will be made available on request.
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